Effect of a WeChat Platform-based Management Intervention on Blood Pressure Control: A Randomized Clinical Trial.

First Affiliated Hospital of Wenzhou Medical University0 sites436 target enrollmentFebruary 18, 2021

ConditionsHypertension

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hypertension
Sponsor: First Affiliated Hospital of Wenzhou Medical University
Enrollment: 436
Primary Endpoint: Proportion with controlled blood pressure at 12 months (defined by ambulatory blood pressure monitoring )
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

WeChat is the largest and most popular social media platform in China, In this study, investigators will evaluate the use of management program delivered via WeChat platform in patients with hypertension.

Registry

clinicaltrials.gov

Start Date

February 18, 2021

End Date

December 31, 2022

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients aged ≥ 18 years with confirmed diagnosis of hypertension
•Office systolic blood pressure (SBP)≥140 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg, or ambulatory blood pressure monitoring (ABPM) indicating 24- hour SBP ≥130 mmHg and/or DBP ≥80 mmHg and/or daytime SBP ≥135 mmHg and/or DBP ≥85 mmHg and/or nocturnal SBP ≥120 mmHg and/or DBP ≥70 mmHg.
•Patients have smart phone and often use WeChat to communicate with others (including written interaction)
•Patients are willing and able to give informed consent for participation in the trial

Exclusion Criteria

•Secondary hypertension
•Hypertensive emergency: defined as severe elevations in BP (SBP ≥180 mmHg and/or DBP≥120mmHg) associated with evidence of new or worsening target organ damage, including hypertensive encephalopathy, intracranial hemorrhage, cerebral hemorrhage, subarachnoid hemorrhage, cerebral infarction, heart failure, acute coronary syndrome (unstable angina, acute myocardial infarction), aortic dissection, perioperative hypertension, preeclampsia, and eclampsia
•Refractory hypertension: defined as failure to control BP despite lifestyle changes and use of at least 5 antihypertensive agents of different classes, including a thiazide-type diuretic and a mineralocorticoid receptor antagonist
•Pregnancy or lactation or having pregnancy plan during the study period
•Life expectancy less than 1 year
•Participation in another clinical study or clinical trial in the 3 months prior to the confirmation of eligibility or current user of WeChat platform provided by hypertension center of the first affiliated hospital of Wenzhou medical university

Outcomes

Primary Outcomes

Proportion with controlled blood pressure at 12 months (defined by ambulatory blood pressure monitoring )

Time Frame: 12 months

mean 24-hour ambulatory blood pressure monitoring (ABPM) \<130/80 mmHg, day time blood pressure \<135/85 mmHg, and nocturnal blood pressure \<120/70 mmHg